Detalhe da pesquisa
1.
PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study.
J Clin Lipidol
; 14(3): 322-330.e5, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32331936
2.
The SYDNEY Device Study: A Multicenter, Randomized, Open-label Usability Study of a 2-mL Alirocumab Autoinjector Device.
Clin Ther
; 42(1): 94-107.e5, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31879033
3.
Usefulness of a personalized algorithm-based discharge checklist in patients hospitalized for acute heart failure.
ESC Heart Fail
; 7(3): 1217-1223, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32320135
4.
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.
J Am Coll Cardiol
; 75(2): 133-144, 2020 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31948641
5.
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Lancet Diabetes Endocrinol
; 7(8): 618-628, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31272931
6.
Corrigendum to PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study Volume 14, Issue 3, May-June 2020, Pages 322-330.e5.
J Clin Lipidol
; 14(5): 741, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33138961
7.
Insulin glargine compared with premixed insulin for management of insulin-naïve type 2 diabetes patients uncontrolled on oral antidiabetic drugs: the open-label, randomized GALAPAGOS study.
J Diabetes Complications
; 29(6): 838-45, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25981123
8.
Triple combination of insulin glargine, sitagliptin and metformin in type 2 diabetes: the EASIE post-hoc analysis and extension trial.
J Diabetes Complications
; 29(1): 134-41, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25283485